Lipocine Inc. (LPCN)

Compare

3.1700

-0.0800

(-2.46%)

At close: 4:00:00 PM EDT

3.0600

-0.11

(-3.47%)

After hours: 7:00:24 PM EDT

Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression

The trial will compare the therapy against a placebo in women aged 15 years and above who are diagnosed with severe PPD.

Clinical Trials Arena 6 days ago

LPCN
-2.46%
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced the initiation of a Phase 3 trial for LPCN 1154 (oral brexanolone) which is in development for the treatment of postpartum depression (PPD).

PR Newswire 7 days ago

LPCN
-2.46%
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the year ended December 31, 2024, and provided a corporate update.

PR Newswire 20 days ago

LPCN
-2.46%
Lipocine Announces FDA Labeling Changes for Testosterone Products

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and Drug Administration (FDA) has recently informed sponsors of approved testosterone products about class-wide labeling changes. This decision follows the Agency's review of the findings from the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypo

PR Newswire 21 days ago

LPCN
-2.46%
Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced receipt of revised regulatory guidance for LPCN 1154 which the Company is developing for postpartum depression (PPD) treatment. As previously disclosed, the Company was scheduled to meet with the U.S. Food and Drug Administration (FDA or the Division) in Q1 2025 to discuss the NDA submission package of LPCN 1154. Followi

PR Newswire last month

LPCN
-2.46%
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation to LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis. LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated

PR Newswire 3 months ago

LPCN
-2.46%
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the publication and discussion of a manuscript "Oral LPCN 1148 Improves Sarcopenia and Hepatic Encephalopathy in Male Patients with Cirrhosis: a randomized, placebo-controlled Phase 2 trial" in the journal Hepatology and discussion at The Liver Meeting (AASLD) 2024 Editor's Cut: Clinical Study Session held on November 16

PR Newswire 4 months ago

LPCN
-2.46%
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the third quarter and nine months ended September 30, 2024 and provided a corporate update.

PR Newswire 4 months ago

LPCN
-2.46%
Lipocine: Q3 Earnings Snapshot

SALT LAKE CITY (AP) — Lipocine Inc. LPCN) on Thursday reported a loss of $2.2 million in its third quarter. The Salt Lake City-based company said it had a loss of 44 cents per share.

Associated Press Finance 4 months ago

LPCN
-2.46%
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced a license, development and supply agreement with to SPC Korea http://spcpharm.co.kr granting exclusive rights to market TLANDO® in South Korea.

PR Newswire 4 months ago

LPCN
-2.46%
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced positive data from its qEEG study of its oral brexanolone, a proprietary bioidentical NAS being developed for the treatment of post-partum depression (PPD). Changes in spectral power (a quantitative measure of the strength or intensity of specific brain wave frequencies) are frequently used to characterize the effects of

PR Newswire 5 months ago

LPCN
-2.46%
Lipocine signs supply and distribution agreement with Pharmalink for Tlando

Lipocine announced an exclusive supply and distribution agreement with Pharmalink to commercialize Tlando, its oral testosterone replacement therapy, in the Gulf Cooperation Council countries consisting of Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman. Under the terms of the agreement, Lipocine received an upfront payment from Pharmalink and, upon Marketing Authorizations in individual GCC countries, Lipocine will provide Tlando drug product to Pharmalink at an agreed

TipRanks 5 months ago

LPCN
-2.46%
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced an exclusive supply and distribution agreement with Pharmalink https://pharmalink.ae/ to commercialize TLANDO®, its oral testosterone replacement therapy, in the Gulf Cooperation Council (GCC) countries consisting of Saudi Arabia, Kuwait, the United Arab Emirates (UAE), Qatar, Bahrain, and Oman.

PR Newswire 5 months ago

LPCN
-2.46%
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that it will host a virtual key opinion leader (KOL) event on LPCN 2401 for improved body composition in obesity management on Wednesday, October 16, 2024 at 11:00 am ET. To register, click here.

PR Newswire 5 months ago

LPCN
-2.46%
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that it will present and meet with investors at the H.C. Wainwright 8th Annual MASH Investor Conference, to take place virtually on October 7, 2024.

PR Newswire 5 months ago

LPCN
-2.46%
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that a poster featuring Phase 2 data on LPCN 2401 will be presented at the Obesity Society's Annual ObesityWeek® conference to be held November 3 – 6, 2024 in San Antonio, TX.

PR Newswire 6 months ago

LPCN
-2.46%
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that Dr. Mahesh V. Patel, President and Chief Executive Officer, will present and meet with investors at the H.C. Wainwright 26th Annual Global Investment Conference being held in-person and virtually on September 9-11, 2024.

PR Newswire 7 months ago

LPCN
-2.46%
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the second quarter ended June 30, 2024 and provided a corporate update.

PR Newswire 7 months ago

LPCN
-2.46%
Lipocine: Q2 Earnings Snapshot

SALT LAKE CITY (AP) — Lipocine Inc. LPCN) on Thursday reported a loss of $3.1 million in its second quarter. On a per-share basis, the Salt Lake City-based company said it had a loss of 56 cents.

Associated Press Finance 7 months ago

LPCN
-2.46%
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced positive topline study results demonstrating bioequivalence of LPCN 1154 to IV brexanolone in an NDA enabling pivotal pharmacokinetic (PK) study. Lipocine is developing LPCN 1154, oral brexanolone, for the treatment of postpartum depression (PPD). The U.S. Food & Drug Administration (FDA) has agreed with Lipocine's propo

PR Newswire 9 months ago

LPCN
-2.46%

Performance Overview

Return	LPCN	S&P 500 (^GSPC)
YTD	-35.04%	-3.58%
1-Year	-36.22%	+8.94%
3-Year	-86.08%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lipocine Inc. (LPCN)

Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Lipocine Announces FDA Labeling Changes for Testosterone Products

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Lipocine: Q3 Earnings Snapshot

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Lipocine signs supply and distribution agreement with Pharmalink for Tlando

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Lipocine: Q2 Earnings Snapshot

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Performance Overview